Overview

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Status:
Terminated

Trial end date:
2018-07-31

Target enrollment:

Participant gender:

Summary

The aim of this study is to evaluate the safety and efficacy of anti PD-L1 antibody + anti CTLA-4 antibody in combination with hormone therapy in patients with hormone receptor positive HER2-negative recurrent or metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Kyoto Breast Cancer Research Network

Treatments:

Antibodies
Fulvestrant
Hormones
Tremelimumab